The outsourcing of biologics development and manufacturing services across the product lifecycle would be driven by the expansion in biopharmaceutical sales and pipeline as well as the complexity of molecules. Additionally, the rising number of molecules (recombinant proteins and antibodies) in the pipeline being developed by small and virtual biotechs (>60%) who lack in-house manufacturing capabilities and expertise to bring their candidates to market would in turn boost the demand for CDMO services.
The global biologics CDMO market is anticipated to witness a CAGR of ~15% to reach $35 billion by 2025, driven by the rising biopharmaceutical end market, rapidly expanding pipelines of cell & gene therapies & new vaccines, and significant VC funding.
Huge Potential for Upturn in Outsourcing Ratio
The outsourcing ratio in biologics manufacturing is much less compared to that for small molecules, providing sufficient opportunity for growth. Companies are looking for CDMOs that can offer significant regulatory leadership and knowledge in all stages, from early-stage discovery to commercialization, due to the biopharma industry’s rising complexity and quick evolution. Furthermore, newer technologies like viral vector, mRNA, and cell & gene therapy are where demand exceeds supply, and capabilities may not exist even in large biopharma thereby offering wide scope for outsourcing to CDMOs.
Market Trend Towards Full-service CDMOs/One-stop-shop Model
As switching costs are significantly higher once cell lines and processes are established, big pharma companies prefer to choose a CDMO that also has early-stage development capabilities. Biopharma companies search for a full-service CDMO handling all services, from cell line development to fill-finish and packaging, due to the inherent complexity of biologics development.
CDMOs Embrace Digital Manufacturing
CDMOs are increasingly resorting to data-driven techniques to make manufacturing more efficient.
“In time, all CDMOs are likely to go digital. Customer demand for high-quality products and information will cause data-driven manufacturing to become the norm.” – Lead Scientist, Tier 1 CDMO, US
Explore Premium Report on Biologics CDMO Market @ https://meditechinsights.com/global-biologics-cdmo-market/
North America is the Largest Market in Biologics CDMO Market
North America is the major biologics CDMO market while APAC is projected to witness the highest CAGR in the next 5 years, hinged on China. To leverage growth opportunities in APAC, in April 2021, Lonza extended its partnership with Chinese firm Junshi Biosciences to advance and manufacture biologics at its site in Guangzhou, China.
Competitive Landscape Analysis of Biologics CDMO Market
The global biologics CDMO market is characterized by a high degree of fragmentation. Some of the leading companies in this market include Lonza, Catalent, Samsung Biologics, Fujifilm, Wuxi Biologics, and Boehringer Ingelheim. While some of the other promising players are Halix, Cobra Biologics, ABL, Biovian, SK Bioscience, IDT, AGC Biologics, Patheon, Abbvie, Novasep, and Emergent Biosolutions.
For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Associate, Medi-Tech Insights
+32 498 86 80 79